The present study sought to combine surprisal analysis, utilizing systems-level data to predict unbalanced processes in each patient tumor, with quantitative analysis of tyrosine phosphorylation mediated signaling networks to identify potential therapeutic targets and therapeutic combinations in TNBC patient-derived xenografts.